AnaptysBio Inc (NASDAQ: ANAB)’s stock price has gone decline by -10.16 in comparison to its previous close of 23.52, however, the company has experienced a 1.10% increase in its stock price over the last five trading days. globenewswire.com reported 2025-06-03 that SAN DIEGO, June 03, 2025 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that investigational rosnilimab, a depleter and agonist targeting PD-1+ T cells, demonstrated a best-in-disease profile in patients with moderate-to-severe rheumatoid arthritis (RA). In the robust, global 424-patient Phase 2b trial, rosnilimab achieved JAK-like efficacy on multiple clinically meaningful measures, including low disease activity (LDA) and remission on the Clinical Disease Activity Index (CDAI), as well as ACR70 response, over a six-month period. Furthermore, responses were then durable for at least two months off drug. Rosnilimab was safe and well tolerated, particularly when compared to standard of care biologics or JAKs.
Is It Worth Investing in AnaptysBio Inc (NASDAQ: ANAB) Right Now?
The 36-month beta value for ANAB is also noteworthy at -0.27. There are mixed opinions on the stock, with 7 analysts rating it as a “buy,” 2 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
The public float for ANAB is 26.48M, and at present, short sellers hold a 33.35% of that float. The average trading volume of ANAB on June 04, 2025 was 737.92K shares.
ANAB’s Market Performance
ANAB stock saw an increase of 1.10% in the past week, with a monthly gain of 1.93% and a quarterly increase of 26.15%. The volatility ratio for the week is 5.23%, and the volatility levels for the last 30 days are 3.38% for AnaptysBio Inc (ANAB). The simple moving average for the past 20 days is 1.74% for ANAB’s stock, with a -7.73% simple moving average for the past 200 days.
Analysts’ Opinion of ANAB
Wolfe Research, on the other hand, stated in their research note that they expect to see ANAB reach a price target of $25. The rating they have provided for ANAB stocks is “Outperform” according to the report published on February 04th, 2025.
H.C. Wainwright gave a rating of “Neutral” to ANAB, setting the target price at $19 in the report published on December 11th of the previous year.
ANAB Trading at 6.03% from the 50-Day Moving Average
After a stumble in the market that brought ANAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -48.85% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at ANAB starting from EcoR1 Capital, LLC, who purchase 65,184 shares at the price of $12.92 back on Dec 30 ’24. After this action, EcoR1 Capital, LLC now owns 7,860,180 shares of AnaptysBio Inc, valued at $842,060 using the latest closing price.
EcoR1 Capital, LLC, the Director of AnaptysBio Inc, purchase 13,268 shares at $12.93 during a trade that took place back on Dec 31 ’24, which means that EcoR1 Capital, LLC is holding 7,873,448 shares at $171,513 based on the most recent closing price.
Stock Fundamentals for ANAB
Current profitability levels for the company are sitting at:
- -0.9 for the present operating margin
- 0.99 for the gross margin
The net margin for AnaptysBio Inc stands at -1.26. The total capital return value is set at -0.27. Equity return is now at value -343.83, with -33.97 for asset returns.
Based on AnaptysBio Inc (ANAB), the company’s capital structure generated 0.31 points at debt to capital in total, while cash flow to debt ratio is standing at -6.54. The debt to equity ratio resting at 0.46. The interest coverage ratio of the stock is -1.62.
Currently, EBITDA for the company is -92.74 million with net debt to EBITDA at 1.0. When we switch over and look at the enterprise to sales, we see a ratio of 4.78. The receivables turnover for the company is 6.26for trailing twelve months and the total asset turnover is 0.27. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.25.
Conclusion
In summary, AnaptysBio Inc (ANAB) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
